TX05 Provides Comparable DFS Benefit to Trastuzumab in Early-Stage HER2+ Breast Cancer - OncLive
6/27/2022 12:00:00 AM2 years 10 months ago
by Chris Ryan
by Chris Ryan
Adjuvant treatment with TX05 resulted in a similar disease-free survival benefit to that of trastuzumab in patients with early-stage HER2-positive breast cancer.
Adjuvant treatment with TX05 resulted in a similar disease-free survival (DFS) benefit to that of trastuzumab (Herceptin) in patients with early-stage HER2-positive breast cancer, according to result… [+4121 chars]
full article...